Literature DB >> 22711375

Griscelli syndrome types 1 and 3: analysis of four new cases and long-term evaluation of previously diagnosed patients.

Deniz Cağdaş1, Tuba Turul Ozgür, Gülten Türkkanı Asal, Ilhan Tezcan, Ayşe Metin, Nathalie Lambert, Geneiveve de Saint Basile, Ozden Sanal.   

Abstract

Griscelli syndrome (GS) is a rare autosomal recessive disorder characterized by partial albinism. Three different types are caused by defects in three different genes. Patients with GS type 1 have primary central nervous system dysfunction, type 2 patients commonly develop hemophagocytic lymphohistiocytosis, and type 3 patients have only partial albinism. While hematopoietic stem cell transplantation is life saving in type 2, no specific therapy is required for types 1 and 3. Patients with GS types 1 and 3 are very rare. To date, only 2 patients with type 3 and about 20 GS type 1 patients, including the patients described as Elejalde syndrome, have been reported. The neurological deficits in Elejalde syndrome were reported as severe neurodevelopmental delay, seizures, hypotonia, and ophthalmological problems including nystagmus, diplopia, and retinal problems. However, none of these patients' clinical progresses were reported. We described here our two new type 1 and two type 3 patients along with the progresses of our previously diagnosed patients with GS types 1 and 3. Our previous patient with GS type I is alive at age 21 without any other problems except severe mental and motor retardation, patients with type 3 are healthy at ages 21 and 24 years having only pigmentary dilution; silvery gray hair, eye brows, and eyelashes. Since prognosis, treatment options, and genetic counseling markedly differ among different types, molecular characterization has utmost importance in GS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711375     DOI: 10.1007/s00431-012-1765-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Kinesin and kinectin can associate with the melanosomal surface and form a link with microtubules in normal human melanocytes.

Authors:  G Vancoillie; J Lambert; A Mulder; H K Koerten; A M Mommaas; P Van Oostveldt; J M Naeyaert
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

2.  Cytoplasmic dynein colocalizes with melanosomes in normal human melanocytes.

Authors:  G Vancoillie; J Lambert; A Mulder; H K Koerten; A M Mommaas; P Van Oostveldt; J M Naeyaert
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

3.  Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome.

Authors:  G Ménasché; E Pastural; J Feldmann; S Certain; F Ersoy; S Dupuis; N Wulffraat; D Bianchi; A Fischer; F Le Deist; G de Saint Basile
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

Review 4.  Pigment cells: a model for the study of organelle transport.

Authors:  Alexandra A Nascimento; Joseph T Roland; Vladimir I Gelfand
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

5.  Griscelli syndrome type 1: a report of two cases and review of the literature.

Authors:  Ellen R Thomas; Lisa J Walker; Sunil Pullaperuma; Beatrice Cooper; Louise A Brueton; Geneviéve de Saint Basile; Mohnish Suri; Angela F Brady
Journal:  Clin Dysmorphol       Date:  2009-07       Impact factor: 0.816

6.  A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport.

Authors:  Molly Strom; Alistair N Hume; Abul K Tarafder; Eleni Barkagianni; Miguel C Seabra
Journal:  J Biol Chem       Date:  2002-04-29       Impact factor: 5.157

7.  Kinesin participates in melanosomal movement along melanocyte dendrites.

Authors:  M Hara; M Yaar; H R Byers; D Goukassian; R E Fine; J Gonsalves; B A Gilchrest
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

8.  Successful bone marrow transplantation in a case of Griscelli disease which presented in accelerated phase with neurological involvement.

Authors:  I Tezcan; O Sanal; F Ersoy; D Uckan; S Kiliç; A Metin; M Cetin; R Akin; C Oner; A Tuncer
Journal:  Bone Marrow Transplant       Date:  1999-10       Impact factor: 5.483

9.  Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1).

Authors:  Gaël Ménasché; Chen Hsuan Ho; Ozden Sanal; Jérôme Feldmann; Ilhan Tezcan; Fügen Ersoy; Anne Houdusse; Alain Fischer; Geneviève de Saint Basile
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

Review 10.  Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation.

Authors:  M Aricò; M Zecca; N Santoro; D Caselli; R Maccario; C Danesino; G de Saint Basile; F Locatelli
Journal:  Bone Marrow Transplant       Date:  2002-06       Impact factor: 5.483

View more
  3 in total

1.  "Road-Dividing Line"-Like Pigmentation of Hair as a Diagnostic Clue for Griscelli Syndrome.

Authors:  Alexandros C Katoulis; Dimitra Daskari; Aikaterini I Liakou; Evangelia Bozi; Dimitra Lianou; Dimitris Rigopoulos
Journal:  Skin Appendage Disord       Date:  2016-10-27

2.  Identification of a Novel MLPH Missense Mutation in a Chinese Griscelli Syndrome 3 Patient.

Authors:  Qiaorong Huang; Yefeng Yuan; Juanjuan Gong; Tianjiao Zhang; Zhan Qi; Xiumin Yang; Wei Li; Aihua Wei
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Hemophagocytic Lymphohistiocytosis in Adults with Intraocular Involvement: Clinicopathologic Features of 3 Cases.

Authors:  M Adelita Vizcaino; Charles G Eberhart; Fausto J Rodriguez
Journal:  Ocul Oncol Pathol       Date:  2017-06-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.